WO2006100226A1 - Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor - Google Patents

Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor Download PDF

Info

Publication number
WO2006100226A1
WO2006100226A1 PCT/EP2006/060887 EP2006060887W WO2006100226A1 WO 2006100226 A1 WO2006100226 A1 WO 2006100226A1 EP 2006060887 W EP2006060887 W EP 2006060887W WO 2006100226 A1 WO2006100226 A1 WO 2006100226A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
group
process according
chain
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/060887
Other languages
French (fr)
Inventor
Juan Sallares
Inés PETSCHEN
Francesc-Xavier Camps
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrer Internacional SA
Original Assignee
Ferrer Internacional SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/886,726 priority Critical patent/US8106202B2/en
Priority to DE602006014677T priority patent/DE602006014677D1/en
Priority to CA2601542A priority patent/CA2601542C/en
Priority to MX2007011238A priority patent/MX2007011238A/en
Priority to AT06708801T priority patent/ATE469901T1/en
Priority to SI200630750T priority patent/SI1879893T1/en
Priority to JP2008502393A priority patent/JP2008533189A/en
Priority to EP06708801A priority patent/EP1879893B1/en
Priority to BRPI0609399-0A priority patent/BRPI0609399A2/en
Priority to PL06708801T priority patent/PL1879893T3/en
Application filed by Ferrer Internacional SA filed Critical Ferrer Internacional SA
Priority to AU2006226412A priority patent/AU2006226412A1/en
Priority to DK06708801.3T priority patent/DK1879893T3/en
Publication of WO2006100226A1 publication Critical patent/WO2006100226A1/en
Priority to IL186040A priority patent/IL186040A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Definitions

  • the present invention concerns a method for manufacturing 1-substituted lfl-imidazo [4, 5-c] quinolin-4-amine compounds, particularly l-isobutyl-lfl-imidazo [4, 5- c] quinolin-4-amine, through their corresponding formamides .
  • the invention also concerns new formamide intermediates .
  • Imiquimod, l-isobutyl-lfl-imidazo [4, 5] quinolin-4-amine is an immune response modifier, useful for treating viral infections, such as genital warts.
  • Imiquimod was firstly disclosed in EP 145340 and has the following structural formula:
  • the present invention provides a method for manufacturing a compound of formula (I) :
  • Ri is selected from the group consisting of straight-chain or branched-chain alkyl containing one to ten carbon atoms and substituted straight-chain or branched-chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight-chain or branched-chain alkyl containing one to four carbon atoms; straight-chain or branched-chain alkenyl containing two to ten carbon atoms and substituted straight-chain or branched-chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight-chain or branched-chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to be
  • R a and R b are independently selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; and Z is selected from the group consisting of alkoxy containing one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1- pyrrolidino, and thioalkyl of one to four carbon atoms; R is selected from the group consisting of lower alkoxy, halogen, and lower alkyl; and n is zero or one, or a pharmaceutically acid addition salt thereof.
  • the present invention shows important advantages over the prior art because high-pressure conditions are not required to conduct the transformation at gentle reaction temperature conditions, thus enabling to perform the process in conventional facilities. Contrary to prior art, reaction times are short and compounds (I) can be isolated almost quantitatively.
  • the present invention comprises:
  • R, R 1 , R 2 and n are as defined above, and X is a halogen selected from the group consisting of chlorine and bromine, with formamide, thus providing the compound of formula (III) :
  • intermediates of general formula (II) wherein X is chlorine can be obtained by known methods, such as those disclosed in US 4,988,815, US 5,578,727, US 5,602,256, US 4,698,348, US 4,689,338 and US 4,929,624.
  • X is bromine
  • intermediates of general formula (II) can be prepared, for instance, from the corresponding N-oxides by reaction with phosphorus oxybromide.
  • the 1-substituted lfl-imidazo [4, 5- c] quinoline-4-formamide (III) intermediates are prepared by reacting 4-halo-lfl-imidazo [4, 5-c] quinolines (II) with formamide in solvolytic conditions or with formamide in another solvent medium, in the presence of a base, in a wide range of temperatures, preferably from about 25 to about 150 0 C, and more preferably from about 70 to about 110 0 C.
  • said solvent medium can be selected from the group of aprotic polar solvents such as dimethylsulfoxide, dimethylacetamide, N-methylpiperidone, N-methylpyrrolidone, dimethylformamide and 1, 3-dimethyl- 2-imidazolidinone, or mixtures thereof, preferably dimethylsulfoxide.
  • aprotic polar solvents such as dimethylsulfoxide, dimethylacetamide, N-methylpiperidone, N-methylpyrrolidone, dimethylformamide and 1, 3-dimethyl- 2-imidazolidinone, or mixtures thereof, preferably dimethylsulfoxide.
  • phase-transfer catalyst is selected from the group consisting of tetrabutylammonium bromide, tetrabutylammonium chloride and tetrabutylammonium hydrogen sulfate. Tetrabutylammonium chloride and tetrabutylammonium hydrogen sulfate are preferred.
  • the bases are selected from the group consisting of alkaline or alkaline earth metal hydroxydes, alkaline or alkaline earth metal carbonates, alkaline or alkaline earth metal bicarbonates, alkaline or alkaline earth metal alkoxides or alkaline or alkaline earth metal hydrides. Alkoxides and more specifically potassium tert-butoxide are preferred.
  • Intermediate formamides (III) can be isolated from the reaction medium or alternatively it is possible to force their complete conversion to corresponding final compounds (I) .
  • compounds (III) When compounds (III) are isolated, then they can be hydrolyzed by known methods of Organic Chemistry. The inventors have preferred not to isolate said intermediates in order to simplify the process.
  • intermediate formamides (III) are not isolated.
  • the present invention comprises the compounds of formula (III) .
  • the present invention comprises the compound of formula (III) which is 1- isobutyl-1-ff-imidazo [4, 5-c] quinoline-4-formamide .
  • the method of the present invention does not require special manufacturing facilities because high pressure is not required and operation temperatures are gentle. Moreover, when the intermediate formamides are not isolated, the final corresponding products are afforded in a unique step with an almost quantitative yield.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

The present invention concerns a method for manufacturing 1-substituted lfl-imidazo [4, 5-c] quinolin-4-amine compounds through their corresponding f ormamides . The invention also concerns new formamide intermediates.

Description

METHOD FOR MAKING 1-SUBSTITUTED IH-IMIDAZO [4 , 5- C]QUINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR
Technical field
The present invention concerns a method for manufacturing 1-substituted lfl-imidazo [4, 5-c] quinolin-4-amine compounds, particularly l-isobutyl-lfl-imidazo [4, 5- c] quinolin-4-amine, through their corresponding formamides . The invention also concerns new formamide intermediates .
Background of the invention
Imiquimod, l-isobutyl-lfl-imidazo [4, 5] quinolin-4-amine, is an immune response modifier, useful for treating viral infections, such as genital warts.
Imiquimod was firstly disclosed in EP 145340 and has the following structural formula:
Figure imgf000002_0001
Some different methods have been disclosed for the preparation of imiquimod and other 1-substituted-lfl- imidazo [4, 5-c] quinolin-4-amines . Certain methods, such as those disclosed in US 4,988,815, US 5,578,727, US 5,602,256, US 4,698,348, US 4,689,338 and US 4,929,624, use the corresponding 4-chloro precursors and their conversion to 4-amino final products implies very energetic conditions comprising heating under pressure in the presence of ammonium hydroxide or ammonia in hermetically sealed reactors for long periods of time. Such required pressures are extremely high, thus forcing to use special manufacturing facilities. Moreover, said processes afford 4-amino final products with moderate yields .
The present invention provides a method for manufacturing a compound of formula (I) :
Figure imgf000003_0001
wherein Ri is selected from the group consisting of straight-chain or branched-chain alkyl containing one to ten carbon atoms and substituted straight-chain or branched-chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight-chain or branched-chain alkyl containing one to four carbon atoms; straight-chain or branched-chain alkenyl containing two to ten carbon atoms and substituted straight-chain or branched-chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight-chain or branched-chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl, (phenyl) ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; R2 is selected from the group consisting of hydrogen; straight-chain or branched-chain alkyl containing one to eight carbon atoms; benzyl; (phenyl) ethyl; and phenyl; the benzyl, (phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, halogen, and
Figure imgf000004_0001
wherein Ra and Rb are independently selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; and Z is selected from the group consisting of alkoxy containing one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1- pyrrolidino, and thioalkyl of one to four carbon atoms; R is selected from the group consisting of lower alkoxy, halogen, and lower alkyl; and n is zero or one, or a pharmaceutically acid addition salt thereof.
The present invention shows important advantages over the prior art because high-pressure conditions are not required to conduct the transformation at gentle reaction temperature conditions, thus enabling to perform the process in conventional facilities. Contrary to prior art, reaction times are short and compounds (I) can be isolated almost quantitatively.
The present invention comprises:
(i) Reacting a 4-halo-lfl-imidazo [4, 5] quinoline (II):
Figure imgf000005_0001
wherein R, R1, R2 and n are as defined above, and X is a halogen selected from the group consisting of chlorine and bromine, with formamide, thus providing the compound of formula (III) :
Figure imgf000005_0002
(III) wherein R, R1, R2 and n are as defined above, and (ii) Converting (III) to final compound (I) by thermal treatment or by acid or basic hydrolysis.
The intermediates of general formula (II) wherein X is chlorine can be obtained by known methods, such as those disclosed in US 4,988,815, US 5,578,727, US 5,602,256, US 4,698,348, US 4,689,338 and US 4,929,624. When X is bromine, intermediates of general formula (II) can be prepared, for instance, from the corresponding N-oxides by reaction with phosphorus oxybromide.
According to the present invention, 1-substituted IH- imidazo [4, 5-c] quinolin-4-amines of general formula (I) can be prepared as shown in Scheme 1 :
oxidizing agent
Figure imgf000006_0001
Figure imgf000006_0002
Figure imgf000006_0003
(III) (I)
Scheme 1 In another embodiment, the 1-substituted lfl-imidazo [4, 5- c] quinoline-4-formamide (III) intermediates are prepared by reacting 4-halo-lfl-imidazo [4, 5-c] quinolines (II) with formamide in solvolytic conditions or with formamide in another solvent medium, in the presence of a base, in a wide range of temperatures, preferably from about 25 to about 1500C, and more preferably from about 70 to about 1100C.
In another embodiment, said solvent medium can be selected from the group of aprotic polar solvents such as dimethylsulfoxide, dimethylacetamide, N-methylpiperidone, N-methylpyrrolidone, dimethylformamide and 1, 3-dimethyl- 2-imidazolidinone, or mixtures thereof, preferably dimethylsulfoxide.
In another embodiment, when aprotic polar solvents are used, addition of a phase-transfer catalyst is optional. The phase-transfer catalyst is selected from the group consisting of tetrabutylammonium bromide, tetrabutylammonium chloride and tetrabutylammonium hydrogen sulfate. Tetrabutylammonium chloride and tetrabutylammonium hydrogen sulfate are preferred.
In another embodiment, the bases are selected from the group consisting of alkaline or alkaline earth metal hydroxydes, alkaline or alkaline earth metal carbonates, alkaline or alkaline earth metal bicarbonates, alkaline or alkaline earth metal alkoxides or alkaline or alkaline earth metal hydrides. Alkoxides and more specifically potassium tert-butoxide are preferred.
Intermediate formamides (III) can be isolated from the reaction medium or alternatively it is possible to force their complete conversion to corresponding final compounds (I) . When compounds (III) are isolated, then they can be hydrolyzed by known methods of Organic Chemistry. The inventors have preferred not to isolate said intermediates in order to simplify the process.
In another embodiment, intermediate formamides (III) are not isolated.
In another embodiment, the present invention comprises the compounds of formula (III) .
In a more preferred embodiment, the present invention comprises the compound of formula (III) which is 1- isobutyl-1-ff-imidazo [4, 5-c] quinoline-4-formamide .
Advantageously, the method of the present invention does not require special manufacturing facilities because high pressure is not required and operation temperatures are gentle. Moreover, when the intermediate formamides are not isolated, the final corresponding products are afforded in a unique step with an almost quantitative yield.
The various aspects of the present invention are described more in details in the non-limitative examples presented hereinafter.
Example 1: l-isobutyl-lfl-imidazo [4, 5-c] quinoline-4- formamide
Potassium tert-butoxide (4.32 g, 0.038 mole), 4.5 mL of dimethylacetamide and 1.53 mL (0.038 mole) of formamide were added in a 50-mL round-bottomed flask, under inert atmosphere followed by stirring for 30 minutes. After addition of 4-chloro-liϊ-imidazo [4, 5-c] quinoline (I g, 3.8 mmoles) , the mixture was heated at 1200C, followed by stirring for 1 hour and then cooled to room temperature. The reaction mixture was filtered followed by washing with abundant water and dried to give 0.4 g of 1- isobutyl-1-ff-imidazo [4, 5-c] quinolin-4-amine. Yield 39%.
The mother waters were concentrated under vacuum and precipitated with methylene dichloride to give 0.5 g of l-isobutyl-lfl-imidazo [4, 5-c] quinoline-4-formamide . Yield 54%. Mp 225-226°C.
IR: 3469, 3177, 3127, 2954, 1687, 1582 cm"1.
1HNMR (CDCl3): 9.98 (d, J=IO.4 Hz, IH, CHO), 9.66 (d, J=IO.8 Hz, IH, NH), 8.13 (s, IH, NCH=N), 8.04 (m, 2H, aromatic), 7.64 (m, IH, aromatic), 7.52 (m, IH, aromatic), 4.36 (d, J=7.2 Hz, 2H, CH2), 2.37 (m, IH, (CHs)2CH), 1.05 (d, J=6.8 Hz, 6H, 2CH3).
13CRMN (CDCl3): 162.8 (CO), 144.27 (NCHN), 143.86 (NCNH), 133.98 (C ar) , 129.25 (CH ar) , 128.22 (CH ar) , 127.83 (CH ar) , 124.87 (CH ar) , 120.03 (CH ar) , 116.82 (Car), 109.97 (CH ar) , 55.19 (CH2), 28.81 ( (CH3) 2CH) , 19.78 (CH3)
Example 2: l-isobutyl-lfl-imidazo [4, 5-c] quinolin-4-amine
Potassium tert-butoxide (2.16 g, 0.019 mole), 4.5 mL of dimethylsulfoxide and 0.76 mL (0.019 mole) of formamide were added in a 50-mL round-bottomed flask, under inert atmosphere followed by stirring for 30 minutes. After addition of 4-chloro-lfl-imidazo [4, 5-c] quinoline (I g, 3.8 mmoles) , the mixture was heated at 1050C, followed by stirring for 2 hours and then cooled to room temperature.
Then 10 mL of water and 6N HCl were sequentially added until pH 8. The reaction mixture was filtered followed by washing with abundant water and dried to give 0.91 g of
1-isobutyl-lfl-imidazo [4, 5-c] quinolin-4-amine. Yield 98%. Example 3: 1-isobutyl-lfl-imidazo [4, 5-c] quinolin-4-amine
Potassium tert-butoxide (3.69 g, 0.033 mole), 5 mL of dimethylacetamide and 1.31 mL (0.033 mole) of formamide were added in a 50 mL round-bottomed flask, under inert atmosphere followed by stirring for 30 minutes. After addition of 4-bromo-liϊ-imidazo [4, 5-c] quinoline (1 g, 3.3 mmoles) , the mixture was heated at 1400C, followed by stirring for 2 hours and then cooled to room temperature. Then 10 mL of water were added and the reaction mixture was filtered followed by washing with abundant water and dried to give 0.75 g of 1-isobutyl-lfl-imidazo [4, 5- c] quinolin-4-amine. Yield 75.4%.

Claims

1. A process for manufacturing lfl-imidazo [4, 5- c] quinolin-4-amine of formula (I):
Figure imgf000011_0001
wherein Ri is selected from the group consisting of straight-chain or branched-chain alkyl containing one to ten carbon atoms and substituted straight-chain or branched-chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight-chain or branched-chain alkyl containing one to four carbon atoms; straight-chain or branched-chain alkenyl containing two to about ten carbon atoms and substituted straight-chain or branched-chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight-chain or branched-chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl, (phenyl) ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;
R2 is selected from the group consisting of hydrogen; straight-chain or branched-chain alkyl containing one to eight carbon atoms; benzyl; (phenyl) ethyl; and phenyl; the benzyl, (phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, halogen, and
Figure imgf000012_0001
wherein Ra and Rb are independently selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; and Z is selected from the group consisting of alkoxy containing one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1- pyrrolidino, and thioalkyl of one to four carbon atoms; R is selected from the group consisting of lower alkoxy, halogen, and lower alkyl; and n is zero or one, that comprises i. reacting a 4-halo-lfl-imidazo [4, 5] quinoline of formula (II) :
Figure imgf000013_0001
(H
wherein R, R1, R2 and n are as defined above; and X is a halogen selected from the group consisting of chlorine and bromine, with formamide, thus obtaining lfl-imidazo [4, 5] quinolin-4-formamide of formula (III) :
Figure imgf000013_0002
(III)
wherein R, R1, R2 and n are as defined above; and ii. removing the formyl group of compound (III)
2. The process according to claim 1, wherein the formamide is under solvolytic conditions or forms a mixture with another solvent, in the presence of a base.
3. The process according to claim 2, wherein the solvent is an aprotic polar solvent.
4. The process according to claim 3, wherein the aprotic polar solvent is selected from the group consisting of dimethylsulfoxide, dimethylacetamide, N- methylpiperidone, N-methylpyrrolidone, dimethylformamide and 1, 3-dimethyl-2-imidazolidinone, or mixtures thereof.
5. The process according to claim 4, wherein the solvent is dimethylsulfoxide .
6. The process according to claim 2, wherein the base is selected from the group consisting of alkaline or alkaline earth metal hydroxydes, alkaline or alkaline earth metal carbonates, alkaline or alkaline earth metal bicarbonates, alkaline or alkaline earth metal alkoxides and alkaline or alkaline earth metal hydrides.
7. The process according to claim 6, wherein the base is an alkaline alkoxide or alkaline earth metal alkoxide.
8. The process according to claim 7, wherein the base is an alkaline alkoxide.
9. The process according to claim 8, wherein the alkaline alkoxide is potassium tert-butoxide.
10. The process according to claim 2, which comprises the optional use of a phase-transfer catalyst when another solvent is used.
11. The process according to claim 10, wherein said phase-transfer catalyst is selected from the group consisting of tetrabutylammonium bromide, tetrabutylammonium chloride and tetrabutylammonium hydrogen sulfate.
12. The process according to claim 11, wherein said phase-transfer catalyst is tetrabutylammonium chloride or tetrabutylammonium hydrogen sulfate.
13. The process according to claim 1, wherein removing said formyl group is performed by a method selected from the group consisting of: a) thermal treatment; b) acid hydrolysis; and, c) basic hydrolysis.
14. The process according to claim 1, wherein the intermediate formamide (III) is not isolated.
15. The process according to claim 1, wherein the temperature is in the range from about 25 to about 1500C.
16. The process according to claim 15, wherein the temperature is in the range from about 70 to about 1100C.
17. A compound of formula (III) according to claim 1.
18. A compound of formula (III) according to claim 17, which is l-isobutyl-lfl-imidazo [4, 5-c] quinoline-4- formamide .
PCT/EP2006/060887 2005-03-21 2006-03-20 Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor Ceased WO2006100226A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BRPI0609399-0A BRPI0609399A2 (en) 2005-03-21 2006-03-20 method for producing 1-substituted 1h-imidazo [4,5-c] quinolin-4-amine compounds and intermediates thereof
CA2601542A CA2601542C (en) 2005-03-21 2006-03-20 Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor
MX2007011238A MX2007011238A (en) 2005-03-21 2006-03-20 Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor.
AT06708801T ATE469901T1 (en) 2005-03-21 2006-03-20 METHOD FOR PRODUCING 1-SUBSTITUTED 1H-IMIDAZOÄ4,5-CUCHINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATE PRODUCTS THEREFOR
SI200630750T SI1879893T1 (en) 2005-03-21 2006-03-20 METHOD FOR MAKING 1-SUBSTITUTED 1H-IMIDAZO?á4,5-C?åQUINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR
JP2008502393A JP2008533189A (en) 2005-03-21 2006-03-20 Process for preparing 1-substituted 1H-imidazo [4,5-c] quinolin-4-amine compounds and intermediates therefor
EP06708801A EP1879893B1 (en) 2005-03-21 2006-03-20 Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor
US11/886,726 US8106202B2 (en) 2005-03-21 2006-03-20 Method for making 1-substituted 1H-imidazo [4,5-C] quinolin-4-amine compounds and intermediates therefor
DE602006014677T DE602006014677D1 (en) 2005-03-21 2006-03-20 PROCESS FOR PREPARING 1-SUBSTITUTED 1H-IMIDAZOE4,5-CUCHINOLINE-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR
PL06708801T PL1879893T3 (en) 2005-03-21 2006-03-20 Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor
AU2006226412A AU2006226412A1 (en) 2005-03-21 2006-03-20 Method for making 1-substituted 1H-imidazo(4,5-c)quinolin-4-amine compounds and intermediates therefor
DK06708801.3T DK1879893T3 (en) 2005-03-21 2006-03-20 Process for the Preparation of 1-Substituted 1H-Imidazo [4,5-c] Quinoline-4-Amine Compounds and Intermediates
IL186040A IL186040A (en) 2005-03-21 2007-09-18 Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102229 2005-03-21
EP05102229.1 2005-03-21

Publications (1)

Publication Number Publication Date
WO2006100226A1 true WO2006100226A1 (en) 2006-09-28

Family

ID=36591271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/060887 Ceased WO2006100226A1 (en) 2005-03-21 2006-03-20 Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor

Country Status (20)

Country Link
US (1) US8106202B2 (en)
EP (1) EP1879893B1 (en)
JP (1) JP2008533189A (en)
KR (1) KR20070113309A (en)
CN (1) CN101146810A (en)
AT (1) ATE469901T1 (en)
AU (1) AU2006226412A1 (en)
BR (1) BRPI0609399A2 (en)
CA (1) CA2601542C (en)
CY (1) CY1111227T1 (en)
DE (1) DE602006014677D1 (en)
DK (1) DK1879893T3 (en)
ES (1) ES2346687T3 (en)
IL (1) IL186040A (en)
MX (1) MX2007011238A (en)
PL (1) PL1879893T3 (en)
PT (1) PT1879893E (en)
RU (1) RU2007139008A (en)
SI (1) SI1879893T1 (en)
WO (1) WO2006100226A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008090550A3 (en) * 2007-01-24 2008-12-11 Chemagis Ltd Imiquimod production process
US7659398B2 (en) 2007-02-14 2010-02-09 Chemagis Ltd. Imiquimod production process
US8357374B2 (en) 2007-02-07 2013-01-22 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US8729088B2 (en) 2009-02-11 2014-05-20 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US9066940B2 (en) 2009-02-06 2015-06-30 Telormedix, Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
US10975075B2 (en) 2015-04-02 2021-04-13 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
EP3950687A1 (en) 2020-08-07 2022-02-09 PHV Pharma Industrial method for synthesising imiquimod from quinoline-2,4-diol applicable to the pharmaceutical use thereof
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974153A1 (en) 2015-02-03 2016-08-11 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689338A (en) * 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323568B2 (en) * 2005-12-12 2008-01-29 Chemagis Ltd. Process for preparing Imiquimod

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689338A (en) * 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IZUMI T ET AL: "1H-Imidazo[4,5-c]quinoline derivatives as novel potent TNF-alpha suppressors: Synthesis and structure-activity relationship of 1-,2-and 4-substituted 1-H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 11, 2003, pages 2541 - 2550, XP002387324 *
VERCEK B ET AL: "Neighboring Group Interaction in Ortho-Substituted Heterocycles. 2. 1,2,4-Oxadiazolylpyridines and Pyrido[2,3-d]pyrimidine 3-Oxides", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 44, no. 10, 1979, pages 1695 - 1699, XP002360944, ISSN: 0022-3263 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US7943771B2 (en) 2007-01-24 2011-05-17 Chemagis Ltd. Imiquimod production process
WO2008090550A3 (en) * 2007-01-24 2008-12-11 Chemagis Ltd Imiquimod production process
US8357374B2 (en) 2007-02-07 2013-01-22 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US8790655B2 (en) 2007-02-07 2014-07-29 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US9050376B2 (en) 2007-02-07 2015-06-09 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US7659398B2 (en) 2007-02-14 2010-02-09 Chemagis Ltd. Imiquimod production process
US9066940B2 (en) 2009-02-06 2015-06-30 Telormedix, Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US8729088B2 (en) 2009-02-11 2014-05-20 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
US10975075B2 (en) 2015-04-02 2021-04-13 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
US11608338B2 (en) 2015-04-02 2023-03-21 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
EP3950687A1 (en) 2020-08-07 2022-02-09 PHV Pharma Industrial method for synthesising imiquimod from quinoline-2,4-diol applicable to the pharmaceutical use thereof
FR3113287A1 (en) 2020-08-07 2022-02-11 Phv Pharma Industrial process for the synthesis of imiquimod from quinoline-2,4-diol applicable to its pharmaceutical use

Also Published As

Publication number Publication date
ATE469901T1 (en) 2010-06-15
IL186040A (en) 2011-11-30
SI1879893T1 (en) 2010-09-30
RU2007139008A (en) 2009-04-27
JP2008533189A (en) 2008-08-21
BRPI0609399A2 (en) 2010-03-30
CN101146810A (en) 2008-03-19
EP1879893B1 (en) 2010-06-02
DK1879893T3 (en) 2010-09-13
AU2006226412A1 (en) 2006-09-28
IL186040A0 (en) 2008-02-09
DE602006014677D1 (en) 2010-07-15
US20090005566A1 (en) 2009-01-01
KR20070113309A (en) 2007-11-28
CA2601542C (en) 2012-09-18
PL1879893T3 (en) 2010-11-30
CA2601542A1 (en) 2006-09-28
PT1879893E (en) 2010-09-02
ES2346687T3 (en) 2010-10-19
CY1111227T1 (en) 2015-06-11
EP1879893A1 (en) 2008-01-23
US8106202B2 (en) 2012-01-31
MX2007011238A (en) 2007-10-18

Similar Documents

Publication Publication Date Title
IL186040A (en) Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor
US11040953B2 (en) Process for the preparation of a diarylthiohydantoin compound
WO2004009593A1 (en) Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via1h-imidazo [4,5-c]quinolin-4-phthalimide intermediates
CZ291368B6 (en) Process and intermediates for preparing 1-substituted-1H-imidazo[4,5-c]quinolin-4-amine
US20070100146A1 (en) Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
US6653477B2 (en) Imidazopyridin-8-ones
HK1116493A (en) Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor
WO2006070408A2 (en) A process for the preparation of substantially pure 4-amino-1-isobutyl-1h-imidazo[4,5-c]-quinoline (imiquimod)
HK1231871A1 (en) A process for the preparation of compound and synthetic intermediates thereof
HK1167136B (en) A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and synthetic intermediates thereof
HK1167136A1 (en) A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and synthetic intermediates thereof
JP2014227362A (en) Method for producing antibacterial compound
KR20070102652A (en) Method for preparing 4-amino-1-isobutyl-1Η-imidazo [4,5-c] -quinoline (imiquimod)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2601542

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006226412

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3405/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/011238

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 186040

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008502393

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12007502070

Country of ref document: PH

Ref document number: 200680009287.8

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006226412

Country of ref document: AU

Date of ref document: 20060320

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006226412

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006708801

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077024147

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007139008

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 11886726

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2006708801

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0609399

Country of ref document: BR

Kind code of ref document: A2